| Execution period | 3 years |
|---|
NSE filing, NSE: JUBLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹943.90
- Market cap
- ₹15,035 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 42.7×Sector 46.1×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Annual General Meeting
Jubilant Pharmova Ltd has issued a Postal Ballot Notice seeking shareholder approval for the private placement issuance of Non-Convertible Debentures.
Jubilant Pharmova Credit Rating
Jubilant Pharmova received a credit rating of IND AA+/Stable from India Ratings and Research for its proposed Non-Convertible Debentures worth ₹1,400 Crore.
- Value
- ₹1,400 Cr
Jubilant Pharmova Other Announcement
Jubilant Pharmova Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Jubilant Pharmova Credit Rating
Jubilant Pharmova received an [ICRA]AA+ (Stable) rating from ICRA for its proposed non-convertible debentures. This confirms the credit assessment for the upcoming debt instrument.
Jubilant Pharmova Debt & Borrowing: ₹800 Cr
Jubilant Pharmova board approved NCD issuance up to ₹800 crore on private placement basis. Postal ballot also sought for NCD authorization up to ₹2,500 crore.
- Value
- ₹800.0 Cr
- Execution
- Upto five years from the Deemed Date of Allotment
Jubilant Pharmova Capacity Expansion: ₹633.1 Cr Investment
Jubilant Pharmova's Radiopharma business will invest CAD 94.5 million (approx. ₹633 Crore) to expand production capacity at its Kirkland facility, aiming to double RUBY-FILL® production.
- Value
- ₹633.1 Cr
- production capacity
- 2.0 times
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.